Integra LifeSciences Holdings Corporation (NasdaqGS:IART) entered into a definitive agreement to acquire 100% stake in Acclarent, Inc. from Ethicon US, LLC for $280 million on December 12, 2023. The consideration consists of $275 million in cash at closing, subject to customary purchase price adjustments, and an additional $5 million upon the achievement of certain regulatory milestones. The acquisition will become part of Integra?s Codman Specialty Surgical (CSS) division.

The transaction expected to be accretive to Integra?s long-range plan. The transaction, subject to customary closing conditions and regulatory approvals and antitrust approvals, is expected to close by the second quarter of 2024. Following the close, transition services, including transition manufacturing services, will be provided for up to four years.

For the year ending 2022, Acclarent reported $110 million revenue. Goldman, Sachs & Co. is serving as exclusive financial advisor and Morgan, Lewis & Bockius LLP is acting as legal advisor to Integra.